| | | Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the
chart below.
|  |
Chairperson |
Member |
Financial Expert |
| | Audit | Compensation | Nominating and Corporate Governance | Scientific | John C. Martin, PhD John C. Martin, PhD
Chairman and Chief Executive Officer, Gilead Sciences
Dr. Martin joined Gilead Sciences in 1990 and currently serves as Chairman of the Board of Directors and Chief Executive Officer. He served as President and Chief Executive Officer from 1996 through May 2008. Prior to joining Gilead, Dr. Martin held several leadership positions in the antiviral chemistry division at Bristol-Myers Squibb and worked for six years with Syntex Corporation, from 1978 until 1984.
Dr. Martin currently serves as Chairman of the Board of Directors of the ... |
| | | | | James M. Denny
James M. Denny
Lead Independent Director, Gilead Sciences Board of Directors
Mr. Denny joined Gilead's Board of Directors in 1996 and was appointed Lead Independent Director in May 2008. He served as Chairman from 2001 until May 2008. Previously, he was Chief Financial Officer and Vice Chair at Sears, Roebuck & Co. and held oversight responsibility for many of the company's operations and staff functions.
Mr. Denny is a member of the advisory boards for several privately-held fund management companies. He is a past Chairman of Northwestern Memorial Hospita... |
| | | | | Paul Berg, PhD Paul Berg, PhD
Nobel Prize Winner, Chemistry
Cahill Professor, Emeritus, Stanford University
Dr. Berg joined Gilead’s Board of Directors in 1998. He previously served as Professor and Chairman of the Department of Biochemistry and Director of the Beckman Center for Molecular and Genetic Medicine at the Stanford University School of Medicine.
Dr. Berg is currently a director and scientific advisor to Affymetrix Inc. He is a member of the U.S. National Academy of Sciences.
In 1980, Dr. Berg was awarded the Nobel Prize for his fundamental studies of the biochemist... |
| | |
|
| John F. Cogan, PhD John F. Cogan, PhD
Senior Fellow, Hoover Institution, Stanford University
Dr. Cogan joined Gilead's Board of Directors in 2005. He is currently the Leonard and Shirley Ely Senior Fellow at the Hoover Institution and Professor of Public Policy at Stanford University, where his research focuses on U.S. budget and fiscal policy, social security and healthcare.
Dr. Cogan has held a number of positions in the U.S. government, including Assistant Secretary for Policy in the U.S. Department of Labor and Associate Director and Deputy Director in the U.S. Office... |
|
| | |
| Etienne F. Davignon Etienne F. Davignon
Minister of State
Vice Chairman, Suez-Tractebel
Mr. Davignon joined Gilead's Board of Directors in 1990. He is currently Vice Chairman of Suez-Tractebel and previously served as Chairman of Société Générale de Belgique, a diversified financial and industrial company.
Mr. Davignon is Chairman of Recticel, CMB and SN Air Holding and a director of Suez and Sofina.
Mr. Davignon has served as the European Community's (EC) Commissioner for Industry and International Markets and as the EC's Vice President for Research, Indu... |
| | |
| | Carla A. Hills Carla A. Hills
Chair and Chief Executive Officer, Hills & Company, International Consultants
Mrs. Hills joined Gilead’s Board of Directors in 2007. She is currently the Chair and Chief Executive Officer of Hills & Company, a firm providing advice to U.S. businesses on investment, trade and risk assessment issues outside the United States.
Mrs. Hills serves on the international advisory boards of J.P. Morgan Chase, Rolls Royce and the Coca-Cola Company. She is Chair of the Inter-American Dialogue, Co-Chair of the Council on Foreign Relations and the International Advisory ... |
| | |
| | Kevin E. Lofton Kevin E. Lofton
President and Chief Executive Officer, Catholic Health Initiatives
Mr. Lofton joined Gilead’s Board of Directors in 2009. He is currently the President and Chief Executive Officer of Catholic Health Initiatives, a Denver-based healthcare system operating the full continuum of services from hospitals to home health agencies throughout the nation. He previously served as Chief Executive Officer of two university hospitals, the University of Alabama at Birmingham Hospital and Howard University Hospital in Washington, D.C. In 2007, Mr. Lofton served as Chairm... |
| |
| | | John W. Madigan
John W. Madigan
Retired Chairman and Chief Executive Officer, Tribune Company
Mr. Madigan joined Gilead's Board of Directors in 2005. He is the retired Chairman and Chief Executive Officer of Tribune Company, a director and former chairman of the Robert R. McCormick Foundation and a director at Boise Cascade.
Mr. Madigan is also a former member of the Defense Business Board of the Department of Defense, an advisor to Madison Dearborn Partners and a director and former chairman of The Chicago Counsel on Global Affairs. He serves as a trustee of Northwestern Universi... |
|
|
| | | Gordon E. Moore, PhD Gordon E. Moore, PhD
Retired Chairman and Chief Executive Officer, Intel Corporation
Dr. Moore joined Gilead’s Board of Directors in 1996, after serving as a member of the company’s Business Advisory Board from 1991 until 1996. Prior to joining Gilead’s board, Dr. Moore co-founded Intel Corporation and served as Chairman, President and Chief Executive Officer.
Dr. Moore is a former Chairman and present Life Trustee of the California Institute of Technology, a member of the National Academy of Engineering and a Fellow of the Royal Society of Engineering (UK). He is ... |
| |
| | | Nicholas G. Moore
Nicholas G. Moore
Retired Global Chairman, PricewaterhouseCoopers
Mr. Moore joined Gilead's Board of Directors in 2004. He is the retired global Chairman of PricewaterhouseCoopers, a professional services firm formed in 1998 by the merger of Coopers & Lybrand and Price Waterhouse. Prior to the merger, Mr. Moore was elected Chairman and Chief Executive Officer of Coopers & Lybrand (U.S.) in 1994 and Coopers & Lybrand International in 1997.
Mr. Moore is the lead independent director of Network Appliance Inc. and a director of Bechtel Group, Inc.,... |
|
|
| | | Richard J. Whitley, MD Richard J. Whitley, MD
Distinguished Professor, Loeb Scholar Chair in Pediatrics, University of Alabama at Birmingham
Dr. Whitley joined Gilead's Board of Directors in 2008. He is a Distinguished Professor, Loeb Scholar Chair in Pediatrics; Director, Division of Pediatric Infectious Diseases; Vice-Chair, Department of Pediatrics; Senior Scientist, Department of Gene Therapy; Senior Scientist, Cancer Research and Training Center; Associate Director for Clinical Studies, Center for AIDS Research; and Co-Director, Center for Emerging Infections and Emergency Preparedness (CEIEP) for the institution.
<... |
| | | |
| Gayle Edlund Wilson Gayle Edlund Wilson
Chair, Ralph M. Parsons Foundation
Mrs. Wilson joined Gilead's Board of Directors in 2001. Mrs. Wilson served as California's First Lady from 1991-1999. She is Chair of the Ralph M. Parsons Foundation, a nonprofit organization that provides grants for higher education, social impact, civic, cultural and health issues.
Mrs. Wilson is also the Chair of the Advisory Board of the California State Summer School for Math and Science (COSMOS), a member of the Board of Trustees of the California Institute of Technology (Caltech)... |
| | |
|
| Per Wold-Olsen Per Wold-Olsen
Retired President, Human Health Intercontinental Division, Merck & Co., Inc.
Mr. Wold-Olsen joined Gilead’s Board of Directors in 2010, after serving as the Chair of the company’s Health Policy Advisory Board since 2007. From 2005 to 2006, Mr. Wold-Olsen served as President of the Human Health Intercontinental Division of Merck & Co., Inc., a leading global pharmaceutical company. From 1997 until 2005, he served as President of Human Health Europe, Middle East/Africa and Worldwide Human Health Marketing for Merck.
Mr. Wold-Olsen is currently Chairman of the... |
| | | |
|
|
Mr. Denny is an ex-officio and non-voting participant of the Audit, Compensation, Nominating and Corporate Governance and Scientific Committees of the Board.
|
